Literature DB >> 23941861

Timing of mortality after severe bleeding and recurrent myocardial infarction in patients with ST-segment-elevation myocardial infarction.

Wouter J Kikkert1, Aeilko H Zwinderman, Marije M Vis, Jan Baan, Karel T Koch, Ron J Peters, Robbert J de Winter, Jan J Piek, Jan G P Tijssen, José P S Henriques.   

Abstract

BACKGROUND: The prognosis of initial survivors of ST-segment-elevation myocardial infarction (STEMI) is affected by both recurrent myocardial infarction (MI) and severe bleeding. The aim of the current study was to investigate how mortality is affected in time after bleeding and recurrent MI. METHODS AND
RESULTS: From January 1, 2003, to July 31, 2008, a total of 2002 patients were treated with primary percutaneous coronary intervention for ST-segment-elevation MI and followed up for the occurrence of recurrent MI and Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) severe bleeding. Primary outcome was all-cause mortality within 4 years of follow-up. In a time-dependent, covariate-adjusted Cox regression model, both bleeding and recurrent MI were associated with an increase in mortality shortly after the adverse event: hazard ratio, 14.37 (95% confidence interval [CI], 7.69-26.84) for the first day after recurrent MI and 5.42 (95% CI, 2.88-10.22) for the first day after bleeding. Thereafter the risk of subsequent mortality gradually decreased but remained elevated long after a recurrent MI (hazard ratio, 4.95 [95% CI, 3.27-7.48] between 1 day and 1 year after recurrent MI and hazard ratio, 2.56 [95% CI, 1.56-4.21] beyond 1 year after recurrent MI), but decreased to nonsignificant level beyond 1 month after the bleeding (hazard ratio, 0.56 [95% CI, 0.27-1.14]).
CONCLUSIONS: The occurrence of both recurrent MI and bleeding in the first year after ST-segment-elevation MI is associated with subsequent mortality. The risk implication of recurrent MI, however, was greater and more sustained over time than that of severe bleeding.

Entities:  

Keywords:  ST-segment–elevation myocardial infarction; major bleeding; primary percutaneous coronary intervention; recurrent myocardial infarction

Mesh:

Year:  2013        PMID: 23941861     DOI: 10.1161/CIRCINTERVENTIONS.113.000425

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  11 in total

1.  Incidence and clinical outcomes of bleeding complications and acute limb ischemia in STEMI and cardiogenic shock.

Authors:  Mohit Pahuja; Sagar Ranka; Omar Chehab; Tushar Mishra; Emmanuel Akintoye; Oluwole Adegbala; Ahmed S Yassin; Tomo Ando; Katherine L Thayer; Palak Shah; Carey D Kimmelstiel; Payam Salehi; Navin K Kapur
Journal:  Catheter Cardiovasc Interv       Date:  2020-05-30       Impact factor: 2.692

2.  Weight of the bleeding impact on early and late mortality after percutaneous coronary intervention.

Authors:  Gjin Ndrepepa; Elena Guerra; Stefanie Schulz; Massimiliano Fusaro; Salvatore Cassese; Adnan Kastrati
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

3.  Long-term ischaemic and bleeding outcomes after primary percutaneous coronary intervention for ST-elevation myocardial infarction in the elderly.

Authors:  Bimmer E P M Claessen; Wouter J Kikkert; Loes P Hoebers; Hassina Bahadurzada; Marije M Vis; Jan Baan; Karel T Koch; Robbert J de Winter; Jan G P Tijssen; Jan J Piek; José P S Henriques
Journal:  Neth Heart J       Date:  2015-09       Impact factor: 2.380

4.  Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.

Authors:  Marco Valgimigli; Francesco Costa; Yuliya Lokhnygina; Robert M Clare; Lars Wallentin; David J Moliterno; Paul W Armstrong; Harvey D White; Claes Held; Philip E Aylward; Frans Van de Werf; Robert A Harrington; Kenneth W Mahaffey; Pierluigi Tricoci
Journal:  Eur Heart J       Date:  2017-03-14       Impact factor: 29.983

5.  Admission lipoprotein-associated phospholipase A2 activity is not associated with long-term clinical outcomes after ST-segment elevation myocardial infarction.

Authors:  Pier Woudstra; Peter Damman; Wichert J Kuijt; Wouter J Kikkert; Maik J Grundeken; Peter M van Brussel; An K Stroobants; Jan P van Straalen; Johan C Fischer; Karel T Koch; José P S Henriques; Jan J Piek; Jan G P Tijssen; Robbert J de Winter
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

6.  Major bleeding after percutaneous coronary intervention and risk of subsequent mortality: a systematic review and meta-analysis.

Authors:  Chun Shing Kwok; Sunil V Rao; Phyo K Myint; Bernard Keavney; James Nolan; Peter F Ludman; Mark A de Belder; Yoon K Loke; Mamas A Mamas
Journal:  Open Heart       Date:  2014-02-13

7.  Major bleeding events in Jordanian patients undergoing percutaneous coronary intervention (PCI): Incidence, associated factors, impact on prognosis, and predictability of the CRUSADE bleeding risk score. Results from the First Jordanian PCR (PCR1).

Authors:  Mohamad Jarrah; Ayman Hammoudeh; Osama Okkeh; Yousef Khader; Sahem Gharaibeh; Laith Nasser; Amro Rasheed; Ayed Al-Hindi; Mohammad Mohealdeen; Haneen Kharabsheh; Hanan Abunimeh; Enas Hijjih; Lina Tashman; Delia Omar; Nadeen Kufoof
Journal:  Anatol J Cardiol       Date:  2017-03-22       Impact factor: 1.596

8.  Trade-off of major bleeding versus myocardial infarction on mortality after percutaneous coronary intervention.

Authors:  Andrew Kei-Yan Ng; Pauline Yeung Ng; April Ip; Lap Tin Lam; Chung-Wah Siu
Journal:  Open Heart       Date:  2022-01

9.  Temporal Trends and Outcome of Patients with Acute Coronary Syndrome and Prior Myocardial Infarction.

Authors:  Katia Orvin; Alon Shechter; Doron Zahger; Vitaly Shklovski; Tal Ovdat; Roy Beigel; Ran Kornowski; Alon Eisen
Journal:  J Clin Med       Date:  2021-11-27       Impact factor: 4.241

10.  Risk of Thromboembolic Events in Patients with Non-Valvular Atrial Fibrillation After Dabigatran or Rivaroxaban Discontinuation - Data from the Ljubljana Registry.

Authors:  Nina Vene; Alenka Mavri; Mirjam Gubenšek; Gregor Tratar; Tjaša Vižintin Cuderman; Maja Pohar Perme; Aleš Blinc
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.